Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 5
2005 29
2006 31
2007 47
2008 71
2009 67
2010 78
2011 110
2012 121
2013 120
2014 132
2015 142
2016 132
2017 165
2018 155
2019 82
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,221 results
Results by year
Filters applied: . Clear all
Page 1
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA. Elewski BE, et al. J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1. doi: 10.1016/j.jaad.2017.08.029. Epub 2017 Oct 6. J Am Acad Dermatol. 2018. PMID: 28993005 Free article. Clinical Trial.
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B, Geng Z, Reyes Servin O, Rich PA. Elewski BE, et al. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2168-2178. doi: 10.1111/jdv.15793. Epub 2019 Sep 4. J Eur Acad Dermatol Venereol. 2019. PMID: 31304993 Free PMC article. Clinical Trial.
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Burmester GR, et al. Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5. Ann Rheum Dis. 2013. PMID: 22562972 Free PMC article. Review.
Psoriasis and its treatment with adalimumab.
Iaconi A, Feldman SR, Balkrishnan R. Iaconi A, et al. Expert Opin Biol Ther. 2010 Jan;10(1):133-52. doi: 10.1517/14712590903493428. Expert Opin Biol Ther. 2010. PMID: 20078231 Review.
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA. Armstrong AW, et al. Am J Clin Dermatol. 2019 Feb;20(1):155-164. doi: 10.1007/s40257-018-0396-z. Am J Clin Dermatol. 2019. PMID: 30417277 Free PMC article. Clinical Trial.
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Gordon KB, et al. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012. Epub 2018 Jul 18. J Eur Acad Dermatol Venereol. 2018. PMID: 29706008 Clinical Trial.
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.
Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group; PSORT consortium. Wilkinson N, et al. J Invest Dermatol. 2019 Jan;139(1):115-123. doi: 10.1016/j.jid.2018.07.028. Epub 2018 Aug 18. J Invest Dermatol. 2019. PMID: 30130616 Free PMC article. Clinical Trial.
Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Rubin DT, et al. J Manag Care Spec Pharm. 2017 Aug;23(8):859-867. doi: 10.18553/jmcp.2017.16272. Epub 2017 Mar 15. J Manag Care Spec Pharm. 2017. PMID: 28737994 Free article.
1,221 results
Jump to page